Loading stock data…
HIND
$1.96-0.07 (-3.45%)
Market ClosedLast close May 1
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vyome Holdings, Inc. in the Healthcare sector is trading at $1.96. The stock is currently near its 52-week low of $1.75, remaining 61.4% below its 200-day moving average. Technical signals show oversold RSI of 23 and bearish MACD signal, explaining why HIND maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 23) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.96
Potential Upside
5%
Whystock Fair Value$2.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Buy
Mean target$15.00+665.3%
Range$15.00 – $15.00
Fundamentals
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$15.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-420.22%
Volume
Today's trading volume
23,936
Recent News
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Vyome Holdings Inc (HIND) showcases promising clinical progress and a robust cash position, despite a significant net loss driven by merger expenses.
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market
Investing.com -- U.S.-India focused clinical-stage pharmaceutical maker Vyome Holdings (Nasdaq: HIND) rang the opening bell at the NASDAQ on Friday, celebrating Indian Independence Day and its trading debut after a reverse merger with ReShape Lifesciences.